Predictive Oncology Inc. (POAI) NASDAQ

Currency In USD

AD

Predictive Oncology Inc.

Address

2915 Commers Drive

Pittsburgh, MN 55121

United States of America (the)

Phone

651 389 4800

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Employees

23

First IPO Date

May 03, 2010

Key Executives

NameTitlePayYear Born
Raymond F. VennareChief Executive Officer & Chairman525,0001953
Joshua BlacherInterim Chief Financial Officer453,9401973
Thomas McLaughlinChief Investment Officer0N/A
Lawrence J. DeLucas D.Sc O.DSenior Vice President of Biologics0N/A
Arlette H. Uihlein FCAPSenior Vice President of Translational Medicine & Drug Discovery and Medical Director0N/A
Sara TurkenSenior Vice President & General Counsel0N/A
AD

Description

Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics division offers extensive clinical diagnostic services, including tumor drug response assessments and genomic profiling, alongside contract research focused on patient-centered drug discovery. This latter service leverages active learning technology for foundational discovery, clinical and translational research, clinical trials, and the development and validation of diagnostics. Meanwhile, the zPREDICTA division excels in crafting organ-specific disease models, providing three-dimensional reconstructions of human tissues that accurately mirror various disease states and simulate drug responses, particularly for evaluating anticancer agents. The Soluble segment delivers services centered on High-Throughput Self-Interaction Chromatography, an automated system proficient at screening additives and excipients in protein formulations to ensure the creation of soluble and physically stable biologic therapeutics. This segment also provides protein stability analysis, specialized kits for swift identification of soluble formulations, and proprietary technologies for the detection and elimination of bacterial endotoxins. The Skyline division markets the STREAMWAY System, a fully automated, wall-mounted device designed to substantially minimize healthcare staff's exposure to blood and other infectious fluids in clinical environments. Furthermore, this division conducts research and development and supplies specialized media that supports the ex-vivo growth of cancer cells while maintaining their original DNA/RNA and proteomic signatures. Founded in 2002, the company was formerly known as Precision Therapeutics Inc. until it adopted the name Predictive Oncology Inc. in June 2019. Its corporate headquarters are situated in Eagan, Minnesota.

AD